查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1856133

全球胜肽合成市場－市場佔有率和排名、總收入和需求預測（2025-2031 年）

Peptide Synthesis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 132 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球胜肽合成市場規模估計為 6.99 億美元，預計到 2031 年將達到 10.94 億美元，在 2025-2031 年預測期內複合年成長率為 6.7%。

胜肽合成是指利用化學或生物化學方法將特定序列的多個胺基酸連接成胜肽鏈的過程。這些胜肽可用作治療藥物、診斷劑、生物標記和研究工具。胜肽通常比蛋白質短，通常由不超過40-60個胺基酸殘基組成，但其結構可能很複雜，可能包含非天然或修飾的胺基酸、環化、與化學基團偶聯以及標記。主要的胜肽合成技術包括固相胜肽合成（SPPS）、液相胜肽合成（LPPS）、混合/匯聚合成法、酵素法和重組表現。合成流程通常包括胺基酸的保護和去保護、胜肽鍵形成（偶聯）、載體/樹脂錨定、純化（層析法步驟、沉澱等）以及嚴格的品管（結構確認、立體化學純度、雜質/殘留溶劑分析）。肽類藥物、診斷和化妝品應用的快速發展，以及對高特異性、低毒性和強生物相容性的需求不斷成長，使得肽合成成為生物製藥和生命科學研究與開發的關鍵組成部分。

目前，肽合成市場正處於曲折點。一方面，基於胜肽的療法在慢性病、代謝性疾病、腫瘤和神經退化等領域日益普及。其高特異性、低全身毒性和新型標靶機制使其在傳統小分子和大蛋白藥物難以發揮作用的領域展現出巨大潛力。另一方面，許多國家（例如美國、歐盟、日本和中國）的政府和監管機構已推出政策，支持創新，簡化新型胜肽和胜肽-寡核苷酸（TIDES）藥物的核准途徑，並縮短臨床試驗和監管審查時間，從而擴大了胜肽合成供應商的市場機會。在技​​術方面，固相合成（SPPS）、液相合成（LPPS）、混合/匯聚合成方法的不斷進步，以及複雜結構（包括非天然氨基酸、環化和胜肽-藥物偶聯物）合成能力的提升，正推動市場朝著更大規模、更高品質和更多樣化的結構發展。此外，下游CDMO/CRO外包需求正在迅速成長。藥物研發企業越來越傾向於將製程開發、規模化生產以及臨床/註冊生產外包給專業的合成/生產營業單位，以降低資本負擔和風險。新興經濟體（例如中國、印度和韓國）也是這一趨勢的強勁驅動力，這得益於不斷成長的醫療需求、對生物技術的投資、不斷下降的生產成本以及有利的政策激勵措施。

然而，肽合成市場並非沒有重大挑戰和風險。首先，合成長肽或複雜胜肽（例如，帶有修飾、非天然殘基、環化或疏水序列的胜肽）時，偶聯效率低、反應不完全、外消旋化和副產物生成等問題會被放大，導致產率降低，純化成本高且難度高。其次，上游原料（高純度保護胺基酸、專用耦合試劑、保護基以及稀有或合成修飾胺基酸）的供應鏈穩定性和成本差異很大。第三，下游純化和品管步驟（層析法、去除殘留試劑、保護基和溶劑、結構確認和立體化學純度測定）需要大量的資本投入、較長的週期和較高的營運成本，尤其是在臨床和商業規模上。各國對胜肽和生技藥品（或其他類別）的定義、監管標準以及環境和化學安全政策的差異，會增加合規成本並導致延誤。最後，競爭壓力和價格戰正在加劇，尤其是在 CDMO/合成服務供應商和以成本為導向的新興市場。

下游需求正朝著多個方向同步發展。治療性胜肽仍然是最大的驅動力。越來越多的胜肽類藥物獲得監管部門核准，研發開發平臺也不斷擴展，尤其是在代謝性疾病（如肥胖症、糖尿病）、腫瘤、內分泌調節和感染疾病等領域。肽-藥物偶聯物和胜肽疫苗已成為多個疾病領域的關鍵研究方向。除了治療性應用外，診斷和成像標記肽，例如生物標記、體外診斷試劑（IVD）以及放射性標記或螢光標記的小肽，需求也在不斷成長，尤其是在精準醫療領域。在化妝品/美容行業，具有抗衰老、修復、促進膠原蛋白生成和抗氧化等功能的胜肽正被積極引入市場，從而推動了消費者和品牌對天然、生物活性和安全成分的更高期望。在自動化和高通量合成工具的推動下，研究和基礎科學需求保持穩定，這促使學術機構和生物技術新興企業尋求更靈活、更快速的客製化胜肽合成服務。總體而言，下游需求正朝著更複雜的結構、更先進的改進、更高的純度和更客製化的應用方向發展，這要求更快的周轉時間和更高的服務品質。

本報告旨在全面概述全球胜肽合成市場，重點關注總銷售收入、市場佔有率和主要企業的排名，並按地區/國家、類型和應用進行分析。

胜肽合成市場規模、估算和預測報告提供了2020年至2031年期間的歷史數據和預測數據，以銷售收入（百萬美元）為單位，2024年為基準年。定量和定性分析有助於讀者制定業務/成長策略、評估市場競爭格局、分析公司在當前市場中的地位，並在胜肽合成領域做出明智的商業決策。

目錄

第1章 市場概覽

  • 胜肽合成產品介紹
  • 全球胜肽合成市場規模預測（2020-2031年）
  • 肽合成市場趨勢及促進因素
  • 先決條件和限制
  • 調查目的
  • 考慮的年數

第2章 競爭分析：依公司分類

  • 全球肽合成公​​司收入排名（2024）
  • 全球肽合成公​​司收入（按公司分類）（2020-2025 年）
  • 主要企業製造地和總部分佈情況
  • 主要企業提供的胜肽合成產品
  • 主要企業何時才能開始大規模生產胜肽合成產品？
  • 胜肽合成市場競爭分析
  • 併購、業務擴張

第3章 按類型分類的章節

  • 簡介：按類型
    • 原料藥和中介軟體
    • 胜肽製劑
  • 全球胜肽合成銷售金額（按類型分類）

第4章 章節：按應用

  • 引言：透過申請
    • 商業的
    • 學術研究
  • 全球胜肽合成產品銷售金額（按應用領域分類）

第5章 章節分類：依地區

  • 全球胜肽合成產品銷售金額（按地區分類）
  • 北美洲
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東和非洲

第6章 章節：依主要國家分類

  • 主要國家/地區胜肽合成銷售金額成長趨勢（2020年、2024年、2031年）
  • 2020-2031年主要國家/地區胜肽合成銷售金額
  • 美國
  • 歐洲
  • 中國
  • 日本
  • 韓國
  • 東南亞
  • 印度

第7章 公司簡介

  • Bachem
  • PolyPeptide
  • CordenPharma
  • AmbioPharm
  • USV Peptides
  • Thermofischer
  • Bio Basic
  • JPT
  • Genscript
  • Xinbang Pharma
  • ScinoPharm
  • SN Biopharm
  • CBL
  • Piramal Pharma
  • CPC Scientific
  • Shenzhen Hanyu

第8章：產業鏈分析

第9章 研究結果與結論

第10章附錄

The global market for Peptide Synthesis was estimated to be worth US$ 699 million in 2024 and is forecast to a readjusted size of US$ 1094 million by 2031 with a CAGR of 6.7% during the forecast period 2025-2031.

Peptide synthesis refers to the process of linking multiple amino acids into a peptide chain in a specified sequence by chemical or biochemical methods. These peptides may serve as therapeutics, diagnostic reagents, biomarkers, or research tools. Peptides are generally shorter than proteins - most often composed of no more than 40-60 amino acid residues - though their structures can be complex, including non-natural or modified amino acids, cyclizations, conjugations with chemical moieties or labels. The main techniques for peptide synthesis include solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), hybrid/convergent methods, enzymatic or recombinant expression methods. The synthetic workflow typically involves protecting and deprotecting amino acids, peptide bond formation (coupling), support/resin anchoring or carrier systems, purification (such as chromatographic steps, precipitations, etc.), and rigorous quality control (structure confirmation, stereochemical purity, impurity/residual solvent analysis). With the rapid expansion of peptide-based drugs, diagnostics, and cosmetic applications, combined with growing demand for high specificity, low toxicity, and strong biocompatibility, peptide synthesis has become a cornerstone in biopharma and life science R&D.

The peptide synthesis market currently stands at a multi-accelerated inflection point. On one side, peptide-based therapeutics are being increasingly recognized in fields such as chronic diseases, metabolic disorders, oncology, and neurodegeneration: their high specificity, low systemic toxicity, and novel targeting mechanisms make them promising where traditional small molecules or large proteins struggle. On another side, governments and regulatory agencies in many countries (including the U.S., EU, Japan, China, etc.) are introducing policies that support innovation, streamline approval pathways for novel peptides or peptide/oligonucleotide (TIDES) drugs, and shorten clinical trial and regulatory review timelines, thereby enlarging market opportunity for peptide synthesis providers. On the technical front, continued progress in solid-phase synthesis (SPPS), liquid-phase methods (LPPS), hybrid / convergent synthesis, and enhanced capabilities for complex structures (including non-natural amino acids, cyclization, peptide-drug conjugates) are pushing the market toward larger scale, higher quality, and greater structural diversity. In addition, downstream CDMO/CRO outsourcing demand is rising sharply: drug developers are increasingly preferring to externalize process development, scale-up, and clinical/registration production to specialized synthesis/manufacturing entities to reduce capital burden and risk. Emerging economies (e.g. China, India, South Korea) are also providing strong growth drivers due to their rising healthcare needs, biotech investment, lower manufacturing cost bases, and favorable policy incentives.

However, the peptide synthesis market is not without substantial challenges and risks. First, synthesizing long or complex peptides (with modifications, non-natural residues, cyclization, hydrophobic sequences etc.) amplifies problems of low coupling efficiency, incomplete reactions, racemization, side-product formation - these reduce yield and make purification expensive and difficult. Second, the supply chain stability and cost volatility for upstream raw materials (high-purity protected amino acids, specialized coupling reagents, protective groups, rare or synthetic modified amino acids) is high; environmental / safety laws regulating chemical reagents and solvents impose increasing constraints. Third, downstream purification and quality control steps (chromatography, removal of residual reagents/protection groups/solvents, structure confirmation, stereochemical purity) require heavy equipment investment, long cycles, and high operating costs, particularly at clinical/commercial scale. Regulatory risk is also real: differing national definitions of peptides vs biologics (or other categories), regulatory standards, and environmental / chemical safety policies may shift, increasing compliance cost or causing delays. Finally, competitive pressures and pricing squeeze are intensifying, especially among CDMOs / synthesis service providers, and in emerging markets focusing on low cost; maintaining high quality, speed, and regulatory compliance becomes a differentiator but also a cost center.

Downstream demand is evolving in several concurrent directions. Therapeutic peptides continue to be the largest pull: more peptide drugs are gaining regulatory approval, and the R&D pipeline is expanding, especially in metabolic disease (e.g. obesity, diabetes), oncology, endocrine regulation, and infectious diseases. In several disease areas, peptide-drug conjugates and peptide vaccines are emerging as key focus areas. Beyond therapeutics, diagnostic and imaging labelled peptides are growing demand, e.g. biomarkers, in vitro diagnostics (IVD) and radiolabelled or fluorescent labelled small peptides, especially in precision medicine. The cosmetics / beauty sector is also actively introducing peptides with anti-aging, repair, collagen-boosting, antioxidative functionalities, with rising consumer and brand expectations for natural or bio-active, safety validated ingredients. Research and basic science needs remain stable, being driven by automation and high-throughput synthesis tools, giving academic institutions and biotech startups need for more flexible, fast, custom peptide synthesis services. Overall, downstream demand is trending toward more complex structures / high modifications / higher purity / more individualized use, and demands for faster turnaround and higher service quality.

This report aims to provide a comprehensive presentation of the global market for Peptide Synthesis, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Peptide Synthesis by region & country, by Type, and by Application.

The Peptide Synthesis market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Synthesis.

Market Segmentation

By Company

  • Bachem
  • PolyPeptide
  • CordenPharma
  • AmbioPharm
  • USV Peptides
  • Thermofischer
  • Bio Basic
  • JPT
  • Genscript
  • Xinbang Pharma
  • ScinoPharm
  • SN Biopharm
  • CBL
  • Piramal Pharma
  • CPC Scientific
  • Shenzhen Hanyu

Segment by Type

  • APIs and Intermediates
  • Peptide preparations

Segment by Application

  • Commercial
  • Academic Research

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Peptide Synthesis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Peptide Synthesis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Peptide Synthesis in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Peptide Synthesis Product Introduction
  • 1.2 Global Peptide Synthesis Market Size Forecast (2020-2031)
  • 1.3 Peptide Synthesis Market Trends & Drivers
    • 1.3.1 Peptide Synthesis Industry Trends
    • 1.3.2 Peptide Synthesis Market Drivers & Opportunity
    • 1.3.3 Peptide Synthesis Market Challenges
    • 1.3.4 Peptide Synthesis Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Peptide Synthesis Players Revenue Ranking (2024)
  • 2.2 Global Peptide Synthesis Revenue by Company (2020-2025)
  • 2.3 Key Companies Peptide Synthesis Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Peptide Synthesis Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Peptide Synthesis
  • 2.6 Peptide Synthesis Market Competitive Analysis
    • 2.6.1 Peptide Synthesis Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Peptide Synthesis Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Synthesis as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 APIs and Intermediates
    • 3.1.2 Peptide preparations
  • 3.2 Global Peptide Synthesis Sales Value by Type
    • 3.2.1 Global Peptide Synthesis Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Peptide Synthesis Sales Value, by Type (2020-2031)
    • 3.2.3 Global Peptide Synthesis Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Commercial
    • 4.1.2 Academic Research
  • 4.2 Global Peptide Synthesis Sales Value by Application
    • 4.2.1 Global Peptide Synthesis Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Peptide Synthesis Sales Value, by Application (2020-2031)
    • 4.2.3 Global Peptide Synthesis Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Peptide Synthesis Sales Value by Region
    • 5.1.1 Global Peptide Synthesis Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Peptide Synthesis Sales Value by Region (2020-2025)
    • 5.1.3 Global Peptide Synthesis Sales Value by Region (2026-2031)
    • 5.1.4 Global Peptide Synthesis Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Peptide Synthesis Sales Value, 2020-2031
    • 5.2.2 North America Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Peptide Synthesis Sales Value, 2020-2031
    • 5.3.2 Europe Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Peptide Synthesis Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Peptide Synthesis Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Peptide Synthesis Sales Value, 2020-2031
    • 5.5.2 South America Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Peptide Synthesis Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Peptide Synthesis Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Peptide Synthesis Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Peptide Synthesis Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Peptide Synthesis Sales Value, 2020-2031
    • 6.3.2 United States Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Peptide Synthesis Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Peptide Synthesis Sales Value, 2020-2031
    • 6.4.2 Europe Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Peptide Synthesis Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Peptide Synthesis Sales Value, 2020-2031
    • 6.5.2 China Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Peptide Synthesis Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Peptide Synthesis Sales Value, 2020-2031
    • 6.6.2 Japan Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Peptide Synthesis Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Peptide Synthesis Sales Value, 2020-2031
    • 6.7.2 South Korea Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Peptide Synthesis Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Peptide Synthesis Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Peptide Synthesis Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Peptide Synthesis Sales Value, 2020-2031
    • 6.9.2 India Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Peptide Synthesis Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Bachem
    • 7.1.1 Bachem Profile
    • 7.1.2 Bachem Main Business
    • 7.1.3 Bachem Peptide Synthesis Products, Services and Solutions
    • 7.1.4 Bachem Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Bachem Recent Developments
  • 7.2 PolyPeptide
    • 7.2.1 PolyPeptide Profile
    • 7.2.2 PolyPeptide Main Business
    • 7.2.3 PolyPeptide Peptide Synthesis Products, Services and Solutions
    • 7.2.4 PolyPeptide Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.2.5 PolyPeptide Recent Developments
  • 7.3 CordenPharma
    • 7.3.1 CordenPharma Profile
    • 7.3.2 CordenPharma Main Business
    • 7.3.3 CordenPharma Peptide Synthesis Products, Services and Solutions
    • 7.3.4 CordenPharma Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.3.5 CordenPharma Recent Developments
  • 7.4 AmbioPharm
    • 7.4.1 AmbioPharm Profile
    • 7.4.2 AmbioPharm Main Business
    • 7.4.3 AmbioPharm Peptide Synthesis Products, Services and Solutions
    • 7.4.4 AmbioPharm Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.4.5 AmbioPharm Recent Developments
  • 7.5 USV Peptides
    • 7.5.1 USV Peptides Profile
    • 7.5.2 USV Peptides Main Business
    • 7.5.3 USV Peptides Peptide Synthesis Products, Services and Solutions
    • 7.5.4 USV Peptides Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.5.5 USV Peptides Recent Developments
  • 7.6 Thermofischer
    • 7.6.1 Thermofischer Profile
    • 7.6.2 Thermofischer Main Business
    • 7.6.3 Thermofischer Peptide Synthesis Products, Services and Solutions
    • 7.6.4 Thermofischer Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Thermofischer Recent Developments
  • 7.7 Bio Basic
    • 7.7.1 Bio Basic Profile
    • 7.7.2 Bio Basic Main Business
    • 7.7.3 Bio Basic Peptide Synthesis Products, Services and Solutions
    • 7.7.4 Bio Basic Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Bio Basic Recent Developments
  • 7.8 JPT
    • 7.8.1 JPT Profile
    • 7.8.2 JPT Main Business
    • 7.8.3 JPT Peptide Synthesis Products, Services and Solutions
    • 7.8.4 JPT Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.8.5 JPT Recent Developments
  • 7.9 Genscript
    • 7.9.1 Genscript Profile
    • 7.9.2 Genscript Main Business
    • 7.9.3 Genscript Peptide Synthesis Products, Services and Solutions
    • 7.9.4 Genscript Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Genscript Recent Developments
  • 7.10 Xinbang Pharma
    • 7.10.1 Xinbang Pharma Profile
    • 7.10.2 Xinbang Pharma Main Business
    • 7.10.3 Xinbang Pharma Peptide Synthesis Products, Services and Solutions
    • 7.10.4 Xinbang Pharma Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Xinbang Pharma Recent Developments
  • 7.11 ScinoPharm
    • 7.11.1 ScinoPharm Profile
    • 7.11.2 ScinoPharm Main Business
    • 7.11.3 ScinoPharm Peptide Synthesis Products, Services and Solutions
    • 7.11.4 ScinoPharm Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.11.5 ScinoPharm Recent Developments
  • 7.12 SN Biopharm
    • 7.12.1 SN Biopharm Profile
    • 7.12.2 SN Biopharm Main Business
    • 7.12.3 SN Biopharm Peptide Synthesis Products, Services and Solutions
    • 7.12.4 SN Biopharm Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.12.5 SN Biopharm Recent Developments
  • 7.13 CBL
    • 7.13.1 CBL Profile
    • 7.13.2 CBL Main Business
    • 7.13.3 CBL Peptide Synthesis Products, Services and Solutions
    • 7.13.4 CBL Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.13.5 CBL Recent Developments
  • 7.14 Piramal Pharma
    • 7.14.1 Piramal Pharma Profile
    • 7.14.2 Piramal Pharma Main Business
    • 7.14.3 Piramal Pharma Peptide Synthesis Products, Services and Solutions
    • 7.14.4 Piramal Pharma Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Piramal Pharma Recent Developments
  • 7.15 CPC Scientific
    • 7.15.1 CPC Scientific Profile
    • 7.15.2 CPC Scientific Main Business
    • 7.15.3 CPC Scientific Peptide Synthesis Products, Services and Solutions
    • 7.15.4 CPC Scientific Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.15.5 CPC Scientific Recent Developments
  • 7.16 Shenzhen Hanyu
    • 7.16.1 Shenzhen Hanyu Profile
    • 7.16.2 Shenzhen Hanyu Main Business
    • 7.16.3 Shenzhen Hanyu Peptide Synthesis Products, Services and Solutions
    • 7.16.4 Shenzhen Hanyu Peptide Synthesis Revenue (US$ Million) & (2020-2025)
    • 7.16.5 Shenzhen Hanyu Recent Developments

8 Industry Chain Analysis

  • 8.1 Peptide Synthesis Industrial Chain
  • 8.2 Peptide Synthesis Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Peptide Synthesis Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Peptide Synthesis Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Peptide Synthesis Market Trends
  • Table 2. Peptide Synthesis Market Drivers & Opportunity
  • Table 3. Peptide Synthesis Market Challenges
  • Table 4. Peptide Synthesis Market Restraints
  • Table 5. Global Peptide Synthesis Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Peptide Synthesis Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Peptide Synthesis Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Peptide Synthesis Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Peptide Synthesis
  • Table 10. Global Peptide Synthesis Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Synthesis as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Peptide Synthesis Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Peptide Synthesis Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Peptide Synthesis Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Peptide Synthesis Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Peptide Synthesis Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Peptide Synthesis Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Peptide Synthesis Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Peptide Synthesis Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Peptide Synthesis Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Peptide Synthesis Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Peptide Synthesis Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Peptide Synthesis Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Peptide Synthesis Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Peptide Synthesis Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Peptide Synthesis Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Peptide Synthesis Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Peptide Synthesis Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Peptide Synthesis Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Bachem Basic Information List
  • Table 32. Bachem Description and Business Overview
  • Table 33. Bachem Peptide Synthesis Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Peptide Synthesis Business of Bachem (2020-2025)
  • Table 35. Bachem Recent Developments
  • Table 36. PolyPeptide Basic Information List
  • Table 37. PolyPeptide Description and Business Overview
  • Table 38. PolyPeptide Peptide Synthesis Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Peptide Synthesis Business of PolyPeptide (2020-2025)
  • Table 40. PolyPeptide Recent Developments
  • Table 41. CordenPharma Basic Information List
  • Table 42. CordenPharma Description and Business Overview
  • Table 43. CordenPharma Peptide Synthesis Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Peptide Synthesis Business of CordenPharma (2020-2025)
  • Table 45. CordenPharma Recent Developments
  • Table 46. AmbioPharm Basic Information List
  • Table 47. AmbioPharm Description and Business Overview
  • Table 48. AmbioPharm Peptide Synthesis Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Peptide Synthesis Business of AmbioPharm (2020-2025)
  • Table 50. AmbioPharm Recent Developments
  • Table 51. USV Peptides Basic Information List
  • Table 52. USV Peptides Description and Business Overview
  • Table 53. USV Peptides Peptide Synthesis Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Peptide Synthesis Business of USV Peptides (2020-2025)
  • Table 55. USV Peptides Recent Developments
  • Table 56. Thermofischer Basic Information List
  • Table 57. Thermofischer Description and Business Overview
  • Table 58. Thermofischer Peptide Synthesis Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Peptide Synthesis Business of Thermofischer (2020-2025)
  • Table 60. Thermofischer Recent Developments
  • Table 61. Bio Basic Basic Information List
  • Table 62. Bio Basic Description and Business Overview
  • Table 63. Bio Basic Peptide Synthesis Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Peptide Synthesis Business of Bio Basic (2020-2025)
  • Table 65. Bio Basic Recent Developments
  • Table 66. JPT Basic Information List
  • Table 67. JPT Description and Business Overview
  • Table 68. JPT Peptide Synthesis Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Peptide Synthesis Business of JPT (2020-2025)
  • Table 70. JPT Recent Developments
  • Table 71. Genscript Basic Information List
  • Table 72. Genscript Description and Business Overview
  • Table 73. Genscript Peptide Synthesis Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Peptide Synthesis Business of Genscript (2020-2025)
  • Table 75. Genscript Recent Developments
  • Table 76. Xinbang Pharma Basic Information List
  • Table 77. Xinbang Pharma Description and Business Overview
  • Table 78. Xinbang Pharma Peptide Synthesis Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Peptide Synthesis Business of Xinbang Pharma (2020-2025)
  • Table 80. Xinbang Pharma Recent Developments
  • Table 81. ScinoPharm Basic Information List
  • Table 82. ScinoPharm Description and Business Overview
  • Table 83. ScinoPharm Peptide Synthesis Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Peptide Synthesis Business of ScinoPharm (2020-2025)
  • Table 85. ScinoPharm Recent Developments
  • Table 86. SN Biopharm Basic Information List
  • Table 87. SN Biopharm Description and Business Overview
  • Table 88. SN Biopharm Peptide Synthesis Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Peptide Synthesis Business of SN Biopharm (2020-2025)
  • Table 90. SN Biopharm Recent Developments
  • Table 91. CBL Basic Information List
  • Table 92. CBL Description and Business Overview
  • Table 93. CBL Peptide Synthesis Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Peptide Synthesis Business of CBL (2020-2025)
  • Table 95. CBL Recent Developments
  • Table 96. Piramal Pharma Basic Information List
  • Table 97. Piramal Pharma Description and Business Overview
  • Table 98. Piramal Pharma Peptide Synthesis Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Peptide Synthesis Business of Piramal Pharma (2020-2025)
  • Table 100. Piramal Pharma Recent Developments
  • Table 101. CPC Scientific Basic Information List
  • Table 102. CPC Scientific Description and Business Overview
  • Table 103. CPC Scientific Peptide Synthesis Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Peptide Synthesis Business of CPC Scientific (2020-2025)
  • Table 105. CPC Scientific Recent Developments
  • Table 106. Shenzhen Hanyu Basic Information List
  • Table 107. Shenzhen Hanyu Description and Business Overview
  • Table 108. Shenzhen Hanyu Peptide Synthesis Products, Services and Solutions
  • Table 109. Revenue (US$ Million) in Peptide Synthesis Business of Shenzhen Hanyu (2020-2025)
  • Table 110. Shenzhen Hanyu Recent Developments
  • Table 111. Key Raw Materials Lists
  • Table 112. Raw Materials Key Suppliers Lists
  • Table 113. Peptide Synthesis Downstream Customers
  • Table 114. Peptide Synthesis Distributors List
  • Table 115. Research Programs/Design for This Report
  • Table 116. Key Data Information from Secondary Sources
  • Table 117. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Peptide Synthesis Product Picture
  • Figure 2. Global Peptide Synthesis Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Peptide Synthesis Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Peptide Synthesis Report Years Considered
  • Figure 5. Global Peptide Synthesis Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Peptide Synthesis Revenue in 2024
  • Figure 7. Peptide Synthesis Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. APIs and Intermediates Picture
  • Figure 9. Peptide preparations Picture
  • Figure 10. Global Peptide Synthesis Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global Peptide Synthesis Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Commercial
  • Figure 13. Product Picture of Academic Research
  • Figure 14. Global Peptide Synthesis Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Peptide Synthesis Sales Value Market Share by Application, 2024 & 2031
  • Figure 16. North America Peptide Synthesis Sales Value (2020-2031) & (US$ Million)
  • Figure 17. North America Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
  • Figure 18. Europe Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 19. Europe Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Asia Pacific Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Asia Pacific Peptide Synthesis Sales Value by Region (%), 2024 VS 2031
  • Figure 22. South America Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. South America Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Middle East & Africa Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Middle East & Africa Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Key Countries/Regions Peptide Synthesis Sales Value (%), (2020-2031)
  • Figure 27. United States Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. United States Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • Figure 29. United States Peptide Synthesis Sales Value by Application (%), 2024 VS 2031
  • Figure 30. Europe Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Europe Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • Figure 32. Europe Peptide Synthesis Sales Value by Application (%), 2024 VS 2031
  • Figure 33. China Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. China Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • Figure 35. China Peptide Synthesis Sales Value by Application (%), 2024 VS 2031
  • Figure 36. Japan Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. Japan Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • Figure 38. Japan Peptide Synthesis Sales Value by Application (%), 2024 VS 2031
  • Figure 39. South Korea Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. South Korea Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • Figure 41. South Korea Peptide Synthesis Sales Value by Application (%), 2024 VS 2031
  • Figure 42. Southeast Asia Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Southeast Asia Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Southeast Asia Peptide Synthesis Sales Value by Application (%), 2024 VS 2031
  • Figure 45. India Peptide Synthesis Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. India Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • Figure 47. India Peptide Synthesis Sales Value by Application (%), 2024 VS 2031
  • Figure 48. Peptide Synthesis Industrial Chain
  • Figure 49. Peptide Synthesis Manufacturing Cost Structure
  • Figure 50. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 51. Bottom-up and Top-down Approaches for This Report
  • Figure 52. Data Triangulation
  • Figure 53. Key Executives Interviewed